Introduction: Pegfilgrastim is administered in multiple clinical settings. A low-dose pegfilgrastim mobilization strategy was evaluated for stem cell collection. Methods: Thirteen consecutive patients undergoing peripheral blood progenitor cell transplantation for hematologic malignancy received a single 6-mg injection of pegfilgrastim after chemotherapy. The, CD34+ cell yield, number of apheresis procedures performed, cytokine cost, and time to engraftment were recorded. Thirteen previous patients who received filgrastim and chemotherapy for mobilization were used for comparison as the control group. Results: Ten of thirteen patients were mobilized successfully. An average of 1.5 apheresis procedures was required. All engrafted successfully in a mean of 10.2 days. The cytokine cost per patient was $3,250. Discussion: Pegfilgrastim as compared with filgrastim resulted in decreased cytokine cost and fewer injections with a comparable number of CD34+ cells mobilized and no significant difference in the number of apheresis collection procedures performed or time to engraftment. Conclusion: Single low-dose pegfilgrastim as part of a mobilization strategy for autologous peripheral blood stem cell transplant is a viable alternative to filgrastim.
|Original language||English (US)|
|Number of pages||5|
|Journal||Journal of Applied Research|
|State||Published - 2006|
- Peripheral blood stem cell transplantation (PBSCT)
ASJC Scopus subject areas
- Pharmacology (medical)